Bortezomib

Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle foun d in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.
Bortezomib